In fact, they evaluated pretreatment 18F-FDG PET/CT scans of 104 patients with advanced EGFR-driven NSCLC undergoing therapy with tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.